Read by QxMD icon Read

bone marrow trasplantment

S Bobillo, P Abrisqueta, B Sánchez-González, E Giné, S Romero, M Alcoceba, E González-Barca, S González de Villambrosía, J M Sancho, P Gómez, L Bento, J Montoro, S Montes, A López, F Bosch
Burkitt's monomorphic posttransplant lymphoproliferative disorder (B-PTLD) is an uncommon subtype of PTLD. Owing to the paucity of this complication, clinical characteristics and outcome has not been fully described. Clinical characteristics and outcomes of 20 patients diagnosed with B-PTLD from 10 transplant centers belonging to the GEL/TAMO group were reviewed. Median time from transplant to B-PTLD was 7.2 years. All the cases fulfill the morphologic and genetic criteria of B-PTLD, whereas Epstein-Barr virus (EBV) was detected in 70% of cases...
December 2018: Annals of Hematology
Juan-Manuel Sancho, Rafael Duarte, Laura Medina, Sergi Querol, Pedro Marín, Anna Sureda
BACKGROUND AND OBJECTIVE: Poor mobilization of peripheral blood stem cells (CD34(+) cells) from bone marrow is a frequent reason for not reaching the autologous stem cell trasplantation (SCT) procedure in patients diagnosed with lymphoma or myeloma. Plerixafor, a reversible inhibitor of the binding of stromal cell-derived factor 1 to its cognate receptor CXCR4, has demonstrated a higher capacity for the mobilization of peripheral blood stem cells in combination with granulocyte colony stimulating factor (G-CSF) compared with G-CSF alone...
September 2, 2016: Medicina Clínica
Christelle Ferrà, Jaime Sanz, Miguel-Angel Díaz-Pérez, Mireia Morgades, Jorge Gayoso, José-Rafael Cabrera, Teresa Villaescusa, María-Antonia Sampol, Francesc Fernández-Avilés, Carlos Solano, Miguel Ortín, Rafael Duarte, Marian Cuesta, Inmaculada Heras, Javier de la Serna, José-María Moraleda, Cristina Barrenetxea, Marta González-Vicent, Guillermo Sanz, Josep-Maria Ribera
Strategies for reversing graft failure (GF) after allogeneic stem cell transplant (SCT) depend on the options available in each situation. GF was reported in 16 Spanish institutions from January 2006 to July 2011. Primary GF was defined as an absolute neutrophil count (ANC) > 0.5 × 10(9)/L not reached by day + 28 after SCT from peripheral blood (PB) or bone marrow (BM) progenitors and by day + 42 after SCT from unrelated cord blood (UCB) progenitors. Secondary GF was defined as a recurrent ANC < 0.5 × 10(9)/L...
March 2015: Leukemia & Lymphoma
R Hladun, I Badell, M González, A M Martínez, J Sánchez de Toledo, M T Olivé, M E González, I Elorza, C Díaz de Heredia
INTRODUCTION: Children with primary immunodeficiency have severe life-threatening infections and a higher prevalence of autoimmune problems, allergy and lymphoproliferative disorders. Allogenic hematopoietic stem cell transplantation has been the only potentially curative option. PATIENTS AND METHODS: Patients with primary immunodeficiency underwent allogenic stem cell transplantation in the period 1985-2011, and registered in the Spanish Working Party for Bone Marrow Transplantation in Children...
February 2015: Anales de Pediatría: Publicación Oficial de la Asociación Española de Pediatría (A.E.P.)
Jose A Pérez-Simón, Rodrigo Martino, Dolores Caballero, David Valcarcel, Noemi Rebollo, Rafael de la Cámara, Javier Pérez de Oteiza, Inmaculada Heras, Maria V Calvo, Jordi Sierra, Jesús F San Miguel
In the current study, we have analyzed the efficacy of cyclosporine A (CSA) plus mycophenolate mofetil (MMF) as graft-versus-host disease (GVHD) prophylaxis in the fludarabine plus melphalan or busulfan reduced intensity regimen (RIC) setting in a series of 44 patients receiving allogeneic transplantation from an unrelated donor. Only 23% were in the first complete remission at the time of transplant. Cumulative incidence of grades II-IV and III-IV acute GVHD (aGVHD) was 53% and 23%, respectively. Fifty-six percent had equal to or greater than grade 2 gut involvement...
June 2008: Biology of Blood and Marrow Transplantation
José Rodríguez, Eulogio Conde, Antonio Gutiérrez, Juan José Lahuerta, Reyes Arranz, Anna Sureda, Javier Zuazu, Alberto Fernández de Sevilla, Maurizio Bendandi, Carlos Solano, Angel León, María Rosario Varela, María Dolores Caballero
BACKGROUND AND OBJECTIVES: Preliminary data on the use of autologous stem cell transplantation (ASCT) as a salvage therapy for peripheral T-cell lymphoma (PTCL) indicate that the results are similar to those obtained in aggressive B-cell lymphomas. The aim of our study was to analyze outcomes of a large series of patients with PTCL with a prolonged follow-up who received ASCT as salvage therapy. DESIGN AND METHODS: Between 1990 and 2004, 123 patients in this situation were registered in the GELTAMO database...
August 2007: Haematologica
José Rodríguez, Eulogio Conde, Antonio Gutiérrez, Reyes Arranz, Marcos Gandarillas, Angel Leon, Jesus Ojanguren, Anna Sureda, Dolores Carrera, Mauricio Bendandi, Jose Moraleda, Jose Maria Ribera, Carmen Albo, Alfonso Morales, Juan Carlos García, Pascual Fernández, Guillermo Cañigral, Juan Bergua, María Dolores Caballero
OBJECTIVES: Angioimmunoblastic T-cell lymphoma (AIL) is a rare lymphoma with a poor prognosis and no standard treatment. Here, we report our experiences with 19 patients treated with high-dose chemotherapy and autologous stem cell transplantation (HDC/ASCT) within the GELTAMO co-operative group between 1992 and 2004. METHODS: The median age at transplantation was 46 yr. Fifteen patients underwent the procedure as front-line therapy and four patients as salvage therapy...
April 2007: European Journal of Haematology
Rocío Parody, Rodrigo Martino, Montserrat Rovira, Lourdes Vazquez, María José Vázquez, Rafael de la Cámara, Cristina Blazquez, Francesc Fernández-Avilés, Enric Carreras, Miguel Salavert, Isidro Jarque, Carmen Martín, Francisco Martínez, Javier López, Antonio Torres, Jorge Sierra, Guilllermo F Sanz
We evaluated the occurrence of severe infections in 192 consecutive adult recipients of volunteer unrelated donor allogeneic hematopoietic stem cell transplants, with a detailed analysis of severe infections after receipt of cord blood transplants (CBTs; n = 48) or bone marrow transplants (BMTs)/peripheral blood stem cell transplants (PBSCTs; n = 144). At a 3-year median follow-up, CBT recipients had a higher risk of developing any severe infection (85% versus 69% in BMT/PBSCT recipients, P < .01). CBT recipients had a higher incidence of severe bacterial infections before day +100, but at 3 years the risks of these and other infections were similar in the CBT and BMT/PBSCT groups...
July 2006: Biology of Blood and Marrow Transplantation
M C del Cañizo, C Martínez, E Conde, C Vallejo, S Brunet, G Sanz, M V Mateos et al.
Allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative therapy for patients with myelodysplastic syndromes (MDSs). We have analyzed the outcome of 81 patients who underwent an allogeneic transplant from an HLA-identical sibling donor. The overall survival (OS) was 31% and disease-free survival was 30% at 5.8 years. Transplant-related complications were the cause of death in 44% and disease progression in 16% of patients. Acute graft-versus-host disease (aGVHD) grades II-IV occurred in 32 cases (39%)...
November 2003: Bone Marrow Transplantation
M Constans, A Sureda, M J Terol, R Arranz, M D Caballero, A Iriondo, I Jarque, E Carreras, J M Moraleda, D Carrera, A León, A López, C Albó, J Díaz-Mediavilla, P Fernández-Abellán, J C García-Ruiz, F Hernández-Navarro, R Mataix, J Petit, M J Pascual, J Rifón, J García-Conde, J M Fernández-Rañada, M V Mateos, J Sierra, E Conde
BACKGROUND: Patients with primary refractory Hodgkin's disease (PR-HD) have a dismal prognosis when treated with conventional salvage chemotherapy. We analyzed time to treatment failure (TTF), overall survival (OS) and clinical variables influencing the outcome in patients undergoing autologous stem cell transplantation (ASCT) for PR-HD and reported to the Grupo Español de Linfomas/Trasplante Autólogo de Médula Osea (GEL/TAMO). PATIENTS AND METHODS: Sixty-two patients, 41 males and 21 females with a median age of 27 years (range 13-55) were analyzed...
May 2003: Annals of Oncology: Official Journal of the European Society for Medical Oncology
Guillermo J Ruiz-Argüelles
We have used a novel method to conduct non-myeloablative stem cell transplantation (NST), making the following changes in previous methods: Use of the cheapest conditioning drugs, tailored number of apheresis sessions in the donors, elimination of ganciclovir and IgG, outpatient conduction when possible, diminished number of transfusions of blood products and diminished number of donor lymphocyte infusions. With this method, we have prospectively conducted 70 allografts in patients with different diseases: Chronic myelogenous leukemia, acute myelogenous leukemia, acute lymphoblastic leukemia, myelodysplasia, thalassemia major, relapsed Hodgkins disease, Blackfan-Diamond syndrome and aplastic anemia...
August 2002: International Journal of Hematology
R Arranz, E Conde, F Rodriguez-Salvanés, F J Pajuelo, R Cabrera, M A Sanz, J Petit, J Bueno, J Maldonado, J Odriozola, J G Conde, S Brunet, E Carreras, A Iriondo, J M Fernández-Rañada, P Marín
A retrospective multicenter study was performed to assess the clinical results in patients with acquired aplastic anemia (AA) allografted over a 19 year period and to identify prognostic factors influencing survival. From April 1978 to December 1997, 176 patients were transplanted. Records from 160 receiving related matched bone marrow transplantation (BMT) were reviewed. Fifty-two percent of the patients were older than 20 years, 5% older than 40; 6.3% were untransfused at BMT and 56.2% had received prior treatments...
February 2002: Bone Marrow Transplantation
A Suárez, L Mozo, A Gayo, A Simó, C Gutiérrez
A deficiency of neonatal T lymphocytes to express CD154 antigen in response to ionomycin and phorbol 12-myrsistate 13-acetate (PMA) stimulation or after CD3 cross-linking has been described. In the present report we describe that CD45RA+ newborn cells are able to synthesize and express CD154 at similar or even higher levels than adult cells in response to ionomycin and cAMP-elevating agents which trigger the protein kinase A (PKA) -mediated metabolic pathway. Peak CD154 protein concentrations in newborn cells were found between 4 and 8 hr after stimulation with ionomycin and dibutyryl cAMP...
August 2000: Immunology
E Carreras, J F Tomás, G Sanz, A Iriondo, C Boqué, J López, R Cabrera, A Sureda, V G de Soria, J Sierra, M A Sanz, A Torres
BACKGROUND AND OBJECTIVE: To analyze the results of unrelated bone marrow transplantation (UDBMT) as treatment for chronic myeloid leukemia (CML) in Spain. DESIGN AND METHODS: Eighty-seven consecutive UDBMT performed in 9 centers between October 1989 and February 1998 were evaluated. This represents more than 95% of UDBMT for CML performed in adult transplant centers in Spain during this period. The patients' median age was 31.5 years (range, 12-49). The median interval from CML diagnosis to UDBMT was 30 months (range, 3-160)...
May 2000: Haematologica
S Zhu, S Chen, H Wei, J Suo
After the transplantation of bone marrow, patients with leukemia are easily infected by kinds of microorganism and die. In this paper, F-mice with the 60Co-gamma irradiation (maximum lethal dose) were transplanted bone marrow, then control the microorganism in the environment. Morever the laminar flow wards for the leukemia patient of bone marrow transplantation were designed according to the data combined with the clinic condition. There is no any infection in twelve patients with bone marrow transplantation from 1989 to 1993...
April 1997: Wei Sheng Wu Xue Bao, Acta Microbiologica Sinica
I Badell, L Igual, P Gomez, E Bureo, J J Ortega, J Cubells, A Muñoz, A Martinez, L Madero, A Verdeguer, A Torres, C Richard, T Olivé, M Daniel, R Bayés
A quality-of-life questionnaire study was administered in a group of 98 disease-free survivors more than 3 years after BMT. All participants were over the age of 17 years at the time of the survey. The transplants were performed between 1981 and 1993 in eight Spanish hospitals. Eighty-three percent of patients had undergone BMT for neoplastic disease. Seventy-three per cent received an allogeneic bone marrow transplantation. A modified version of a questionnaire applied in Stanford Hospital to evaluate quality of life in adults after BMT was used...
April 1998: Bone Marrow Transplantation
I Badell, J J Ortega, A Muñoz, E Bureo, L Madero, T Olivé, J Cubells, M S Maldonado, J Baro, M A Díaz
PURPOSE: Using the data from the GETMON ("Grupo Español de Trasplante de Medula Osea en Niños") we carried out a retrospective analysis of the results of allogeneic bone marrow transplantation (alloBMT) compared to autologous bone marrow transplantation (ABMT) in 113 paediatric patients with acute lymphoblastic leukaemia (ALL) in second remission. Transplants were performed by the following centers, from April 1983 to December 1991: H. Vall d'Hebrón and H. Sant Pau from Barcelona, H...
April 1996: Sangre
E León, R Sosa
The first case of allogeneic bone marrow transplantation in acute myelogenous leukemia (AML) done in Mexico is reported. The patient was a 26 year old Mexican woman who in October 1987 was diagnosed of having AML of the M2 subtype. After three cycles of the TADOP regimen (6-thioguanine, cytosine-arabinoside, doxorubicin, vincristine & prednisone), the patient entered complete remission. Unfortunately, after a seven month period of remission she suffered a relapse which was refractory to a new chemotherapy cycle...
July 1992: Revista de Investigación Clínica; Organo del Hospital de Enfermedades de la Nutrición
P L Weiden, R Storb, T C Graham, M L Schroeder
Severe hereditary haemolytic anaemia related to pyruvate kinase deficiency occurs in Basenji dogs homozygous for this autosomal recessive defect. In the current study, three anaemic dogs were treated by total body irradiation and marrow transplantation from non-anaemic histocompatible littermates with resultant complete correction of their haemolytic anaemia. The possible use of marrow transplantation for life-threatening haemolytic anaemias in man is discussed.
July 1976: British Journal of Haematology
O I Sokova, G M Volgareva
No chromosome aberrations were found in the bone marrow cells and Djungarian hamster tumor cells and bone-marrow cells of thymectomized mice receiving different doses of fluorafur and 5-fluoruracil in vivo. The time of exposure to these antitumor drugs varied from 2 to 72 hours. 12% of aberrant metaphases under 400 mg/Kg of fluorafur and 38%--under 200 mg/Kg of 5-fluoruracil were found in cells of human colonic tumor trasplanted into thymectomized mice.
1977: Voprosy Onkologii
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"